Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Third Dose of mRNA-1273 Vaccine in Renal Transplants With Immunological Failure
NCT04930770Phase 2Withdrawn
- Start
- Sep 2021
- Primary completion
- Dec 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
01
Overview
Phase 2, open-label, single-arm trial of elasomeran in coronavirus disease 2019 (COVID-19). Primary endpoint: Number of patients with development of cellular and humoral immunity against SARS-CoV-2 at 2 weeks. Planned start Sep 2021; status: withdrawn.
02
Drugs
elasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04930770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04930770.